NIAGARA第三阶段试验显示,IMFINZI显著降低了膀胱癌复发和与外科手术相结合的死亡风险。 NIAGARA Phase III trial shows IMFINZI® significantly reduces bladder cancer recurrence and death risk when combined with surgery.

尼雅加拉III期试验发现,与单独使用新辅助化疗相比,术前治疗IMFINZI® (杜尔瓦卢马布) 显著降低了肌肉侵入性膀癌患者的癌症复发风险32%,死亡风险25%. The NIAGARA Phase III trial found that a perioperative regimen of IMFINZI® (durvalumab) significantly reduced the risk of cancer recurrence by 32% and death by 25% in patients with muscle-invasive bladder cancer, compared to neoadjuvant chemotherapy alone. 这表明,将IMFINZI与外科手术相结合可为该患者群体提供更有效的治疗选择。 This suggests that combining IMFINZI® with surgery may offer a more effective treatment option for this patient group.